TOKYO -- The discoveries by newly anointed Nobel laureates Tasuku Honjo of Japan and James Allison of the U.S. have opened up a market for revolutionary cancer treatments that is expected to quintuple to 5 trillion yen ($43.8 billion) by 2025.
The work by the two immunologists, who share the Nobel Prize in physiology or medicine, created the foundation upon which the blockbuster immunotherapy drug Opdivo was developed.
